Although the cost-effectiveness analysis of the PD-1/PD-L1 inhibitor for GI tumor patients has not yet been reported, it is foreseeable that it will be improved by developing alternative agents, reducing drug costs and selecting appropriate patients. This evidence concerns the gene PDCD1 and digestive system neoplasm.